KRAKOW, Poland, July 25,
2019 /PRNewswire/ -- Selvita, S.A. (WSE: SLV), a
leading clinical stage drug discovery company committed to
developing innovative medicines for treatment of patients with
cancer, announced today the appointment of Setareh Shamsili, M.D.,
Ph.D., to the role of Chief Medical Officer. A seasoned veteran,
Dr. Shamsili brings more than 20 years of clinical oncology and
drug development experience to the company.
"Setareh's impressive track record advancing novel oncology
compounds through clinical development will significantly
strengthen Selvita's capabilities in moving our first clinical
study forward in the U.S. with SEL120, our fully proprietary oral,
selective inhibitor of CDK8 for the treatment of acute myeloid
leukemia and myelodysplastic syndromes," commented Pawel
Przewiezlikowski, Chief Executive Officer of Selvita. "We are
pleased to welcome Dr. Shamsili to our executive team and look
forward to her strategic leadership as we advance our rich pipeline
of novel anti-cancer therapeutic candidates."
"I feel honored to become a member of the Selvita executive
team," said Dr. Shamsili. "This role provides the opportunity to
make key contributions to the advancement of the novel and
promising anti-cancer candidates of the Selvita pipeline and bring
new hope to cancer patients. Selvita candidates are generated from
its own, well-established discovery platform, which enables a
steady strategic renewal of the pipeline. The discovery platform
allows evaluation of several novel first-in-class or best-in-class
compounds in a parallel manner. In addition, each platform program
addresses a distinct mechanism of action and is staffed with a team
of highly talented scientists supported by experienced clinical
professionals."
Dr. Shamsili has been an independent industry consultant for a
number of immuno-oncology companies in the U.S. and Europe, contributing to programs in various
stages of development and therapeutic classes including small
molecules, antibodies and cancer vaccines, with her latest position
being the interim Chief Medical Officer at AxImmune, a U.S.-based
immuno-oncology company. She was the first Chief Medical Officer of
Merus NV, where she brought the initial two candidates to the
clinic for development in acute myeloid leukemia and the treatment
of solid tumors. During her tenure at Merus until about end 2016,
Dr. Shamsili was instrumental in providing support for successful
fundraising activities and establishing strategic alliances. From
2006-2012, Dr. Shamsili served as Global Medical Leader Oncology at
Astellas Pharma Global Development. Dr. Shamsili received her M.D.
degree and board certification in internal medicine from the
National University of Medical Sciences
in Tehran, with a focus in
oncology, and her Ph.D. in Oncology from the international Erasmus
Medical University in Rotterdam.
She recently also has completed the University
of Pennsylvania Wharton Business School Global Strategic
Leadership Program.
About Selvita
Selvita is developing novel small molecule therapies that
address emerging targets and novel pathways in oncology with
industry-leading research expertise. Pipeline candidates make use
of diverse therapeutic mechanisms driven by emerging knowledge of
cancer biology, including small molecules directed at kinase,
synthetic lethality, immuno-oncology and cancer metabolism targets.
SEL120 is a selective CDK8 kinase inhibitor in Phase 1 clinical
development for the treatment of acute myeloid leukemia and
myelodysplastic syndromes, with potential for expansion to
additional hematological and solid malignancies. SEL24/MEN1703 is a
dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in
Phase 1/2 clinical development for the treatment of acute myeloid
leukemia. Selvita is headquartered in Krakow, Poland, with offices in the U.S. and U.K.
Ardigen, a provider of precision medicine and artificial
intelligence services, and NodThera, a company developing a new
class of medicines to treat chronic inflammation, were launched by
Selvita. In March 2019, Selvita
announced the intent to split its oncology development and research
services divisions into separate companies.
Contact:
Julia Balanova
(investors)
+1-646-378-2936
jbalanova@troutgroup.com
Rich Allan
(media)
+1-646-378-2958
rallan@troutgroup.com
Piotr Ksiazek (investors and
media, Poland)
+48-501-988-693
p.ksiazek@innervalue.pl
Natalia Baranowska
(corporate)
+48-784-069-418
natalia.baranowska@selvita.com
View original
content:http://www.prnewswire.com/news-releases/selvita-appoints-setareh-shamsili-md-phd-as-chief-medical-officer-300890505.html
SOURCE Selvita